These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26414905)

  • 21. The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.
    Hayes CN; Imamura M; Chayama K
    Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):103-113. PubMed ID: 27936974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
    Morio K; Imamura M; Kawakami Y; Morio R; Kobayashi T; Yokoyama S; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Makokha GN; Hayes CN; Aikata H; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
    J Gastroenterol Hepatol; 2017 Mar; 32(3):645-650. PubMed ID: 27513614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.
    Hirashima N; Iwase H; Shimada M; Ryuge N; Imamura J; Ikeda H; Tanaka Y; Matsumoto N; Okuse C; Itoh F; Yokomaku Y; Watanabe T
    Clin J Gastroenterol; 2017 Feb; 10(1):41-46. PubMed ID: 27766544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma.
    Jiang H; Kandoussi H; Zeng J; Wang J; Demers R; Eley T; He B; Burrell R; Easter J; Kadiyala P; Pursley J; Cojocaru L; Baker C; Ryan J; Aubry AF; Arnold ME
    J Pharm Biomed Anal; 2015 Mar; 107():409-18. PubMed ID: 25676854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis.
    Uojima H; Murakami S; Nakatani S; Hidaka H; Takeuchi A; Tanaka Y; Inoue T; Yamane K; Kubota K; Nakazawa T; Shibuya A; Tanaka Y; Koizumi W
    Intern Med; 2018 Apr; 57(7):951-956. PubMed ID: 29225269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.
    Kan H; Imamura M; Uchida T; Hiraga N; Hayes CN; Tsuge M; Abe H; Aikata H; Makokha GN; Chowdhury S; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    J Infect Dis; 2016 Dec; 214(11):1687-1694. PubMed ID: 27651415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients.
    Ueno T; Osawa M; Shiozaki T; Green M; Garimella T
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):903-913. PubMed ID: 30667592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
    Kai Y; Hikita H; Tatsumi T; Nakabori T; Saito Y; Morishita N; Tanaka S; Nawa T; Oze T; Sakamori R; Yakushijin T; Hiramatsu N; Suemizu H; Takehara T
    J Gastroenterol; 2015 Nov; 50(11):1145-51. PubMed ID: 26208695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beclabuvir for the treatment of hepatitis C.
    Gentile I; Zappulo E; Buonomo AR; Maraolo AE; Borgia G
    Expert Opin Investig Drugs; 2015; 24(8):1111-21. PubMed ID: 26156630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
    Tao W; Gan T; Lu J; Zhong J
    Antiviral Res; 2017 Mar; 139():18-24. PubMed ID: 28025084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
    Ahmed AM; Doheim MF; Mattar OM; Sherif NA; Truong DH; Hoa PTL; Hirayama K; Huy NT
    J Med Virol; 2018 May; 90(5):907-918. PubMed ID: 28892235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
    Eley T; Garimella T; Li W; Bertz RJ
    Clin Pharmacokinet; 2015 Dec; 54(12):1205-22. PubMed ID: 26177803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.
    Piroth L; Paniez H; Taburet AM; Vincent C; Rosenthal E; Lacombe K; Billaud E; Rey D; Zucman D; Bailly F; Bronowicki JP; Simony M; Diallo A; Izopet J; Aboulker JP; Meyer L; Molina JM;
    Clin Infect Dis; 2015 Sep; 61(5):817-25. PubMed ID: 25977266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
    Nakamura Y; Imamura M; Kawakami Y; Teraoka Y; Daijo K; Honda F; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Chayama K
    J Med Virol; 2017 Apr; 89(4):665-671. PubMed ID: 27602542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.
    Eley T; Sevinsky H; Huang SP; He B; Zhu K; Kandoussi H; Gardiner D; Grasela DM; Bertz R; Bifano M
    Clin Drug Investig; 2014 Sep; 34(9):661-71. PubMed ID: 25117173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
    J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
    Barrail-Tran A; Vincent C; Furlan V; Rosa I; Rosenthal E; Cheret A; Molina JM; Taburet AM; Piroth L;
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7903-5. PubMed ID: 26438504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.
    Pasquinelli C; McPhee F; Eley T; Villegas C; Sandy K; Sheridan P; Persson A; Huang SP; Hernandez D; Sheaffer AK; Scola P; Marbury T; Lawitz E; Goldwater R; Rodriguez-Torres M; Demicco M; Wright D; Charlton M; Kraft WK; Lopez-Talavera JC; Grasela DM
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1838-44. PubMed ID: 22290978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
    Signorovitch JE; Betts KA; Song Y; Sorg RA; Li J; Behl AS; Kalsekar A
    J Comp Eff Res; 2015 Nov; 4(6):593-605. PubMed ID: 26159375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.